Search hospitals
>
Washington
>
Seattle
Seattle Cancer Care Alliance
Claim this profile
Seattle, Washington 98109
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Prostate Cancer
Conducts research for Pancreatic Cancer
426 reported clinical trials
43 medical researchers
Summary
Seattle Cancer Care Alliance is a medical facility located in Seattle, Washington. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer and other specialties. Seattle Cancer Care Alliance is involved with conducting 426 clinical trials across 494 conditions. There are 43 research doctors associated with this hospital, such as Michael J Wagner, MD, Michael Schweizer, Christina S. Baik, and Andrew L. Coveler.
Area of expertise
Cancer
Seattle Cancer Care Alliance has run 73 trials for Cancer. Some of their research focus areas include:
Lung Cancer
Seattle Cancer Care Alliance has run 71 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Michael J Wagner, MD
Dana-Farber Cancer Institute
5 years of reported clinical research
Michael Schweizer
Fred Hutch/University of Washington Cancer Consortium
1 year of reported clinical research
Christina S. Baik
Fred Hutchinson Cancer Center
6 years of reported clinical research
Andrew L. Coveler
Fred Hutchinson Cancer Research Center
5 years of reported clinical research
Clinical Trials running at Seattle Cancer Care Alliance
Prostate Cancer
Cancer
Lung Cancer
Breast Cancer
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Ovarian Cancer
Pancreatic Cancer
Multiple Myeloma
Relapse
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting
2 awards
Phase 3
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting
2 awards
Phase 3
30 criteria
Genomics
for Prostate Cancer
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene mutations in men with prostate cancer as well as the course of their disease to better understand how gene mutations relate to the way the cancer progresses and responds to treatment. Eligibility: Adult males 18 and older with prostate cancer who have at least one of the gene mutations researchers want to study and/or have been treated for their cancer and have had complete elimination of their cancer or stable disease for a long time. Design: Participants will be screened with a review of their medical records. Their gene test results will be reviewed, if available. They will be asked questions over the phone or in person. Participants do not need to visit the NIH for this study. But if they visit NIH for another study, their data and test results will be collected. They may give blood and urine samples. They may give leftover tumor samples. These samples will be used to study their genes. Participants who do not come to NIH on regular basis will be contacted every 6 months by phone or e-mail. They will be asked questions about their health. Data from their medical records will be collected. Participants will have testosterone and prostate-specific antigen (PSA) tests. Participants may be invited to NIH to give blood samples for research. Participants on this study will be followed for life.
Recruiting
1 award
N/A
5 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Seattle Cancer Care Alliance?
Seattle Cancer Care Alliance is a medical facility located in Seattle, Washington. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer and other specialties. Seattle Cancer Care Alliance is involved with conducting 426 clinical trials across 494 conditions. There are 43 research doctors associated with this hospital, such as Michael J Wagner, MD, Michael Schweizer, Christina S. Baik, and Andrew L. Coveler.
Where is Seattle Cancer Care Alliance located?
**Seattle Cancer Care Alliance** - **Address:** 825 Eastlake Ave E, Seattle, WA.
Who should I call to ask about financial aid or insurance network?
Seattle Cancer Care Alliance (SCCA) provides financial assistance to eligible patients, including those with health insurance, based on income requirements. Patients interested in applying for financial assistance can contact the facility directly or submit an application. For assistance with insurance benefits and care options, SCCA's Patient Financial Services team is available at 800.304.1763.
What insurance does Seattle Cancer Care Alliance accept?
Seattle Cancer Care Alliance (SCCA) accepts a wide range of insurance plans, including but not limited to Premera Blue Cross, Regence BlueShield, Kaiser Permanente, and Medicare. It is important to verify coverage with your insurance provider as some plans, especially those from the Washington Healthplanfinder, may not cover cancer treatment at SCCA. SCCA is also in-network with numerous other insurance providers such as Boeing BCBS, Cigna PPO, Community Health Plan of Washington, and many more. Always confirm that your plan covers the necessary care at SCCA before scheduling an appointment.
What awards or recognition has Seattle Cancer Care Alliance received?
Seattle Cancer Care Alliance (SCCA) ranks among the top ten cancer hospitals in the nation, according to U.S. News & World Report, and is the leading cancer hospital in the Pacific Northwest. It has earned "High Performing" ratings for both colon cancer surgery and lung cancer surgery, showcasing care that surpasses the national average.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.